2003 Disease Immune Response Vaccine 
Drug Discovery World
MAY 15, 2024
Researchers have developed a new vaccine technology that can provide protection against a broad range of coronaviruses with potential for future disease outbreaks – including ones we don’t know about yet. Building protective vaccines before a pandemic emerges “We don’t have to wait for new coronaviruses to emerge.
The Pharma Data
OCTOBER 18, 2021
Northwestern Medicine scientists have shown for the first time that coronavirus vaccines and prior coronavirus infections can provide broad immunity against other, similar coronaviruses. The findings build a rationale for universal coronavirus vaccines that could prove useful in the face of future epidemics.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
NIH Director's Blog: Drug Development
MAY 21, 2020
Science, 2020 We now know that the immune system of nearly everyone who recovers from COVID-19 produces antibodies against SARS-CoV-2, the novel coronavirus that causes this easily transmitted respiratory disease [1]. In the U.S. Stay tuned for more information about these potentially significant advances in the next few months.
NIH Director's Blog: Drug Development
MARCH 18, 2021
He uses these fundamental insights to guide the design of vaccines and therapeutics, including promising monoclonal antibodies. These days, the Veesler lab has been hard at work to understand SARS-CoV-2 and the human immune response to the virus.
Drug Target Review
OCTOBER 4, 2023
Antibody-drug conjugates (ADCs) have been a groundbreaking approach to cancer treatment with their ability to deliver cytotoxic drugs directly to diseased cells while sparing healthy tissues. 10 Proteasome inhibitors Since the approval of Bortezomib in 2003, 11 new proteasome inhibitors have emerged with reduced side effects.
Expert insights. Personalized for you.
130 
Let's personalize your content